In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 1.03 million shares changing hands with its beta currently measuring 2.50. Company’s recent per share price level of $0.58 trading at $0.0 or 0.17% at ring of the bell on the day assigns it a market valuation of $148.28M. That closing price of ADAP’s stock is at a discount of -253.45% from its 52-week high price of $2.05 and is indicating a premium of 8.62% from its 52-week low price of $0.53.
For Adaptimmune Therapeutics Plc ADR (ADAP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.89. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Upright in the green during last session for gaining 0.17%, in the last five days ADAP remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $0.58 price level, adding 4.71% to its value on the day. Adaptimmune Therapeutics Plc ADR’s shares saw a change of 7.57% in year-to-date performance and have moved 0.10% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of 1.67% in past 30-days.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 80.67% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -72.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -72.41% for stock’s current value.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
This year revenue growth is estimated to rise 204.78% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 8.77M for the same. And 3 analysts are in estimates of company making revenue of 6.3M in the next quarter. Company posted 231k and 5.68M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.30% during past 5 years.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ADAP for having 38.97 million shares of worth $38.0 million. And as of 2024-06-30, it was holding 2.5415 of the company’s outstanding shares.
The second largest institutional holder is BANK OF AMERICA CORP /DE/, which was holding about 4.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.9239 of outstanding shares, having a total worth of $4.53 million.
